What is Prolong Pharmaceuticals, LLC.?
Prolong Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to pioneering novel therapies for challenging conditions, with a strategic focus on Central Nervous System (CNS), Hematology, and Respiratory Disorders. The company aims to address critical unmet medical needs in areas such as Ischemia and Hypoxia, relevant to conditions including Stroke, Sickle Cell Disease, and Cystic Fibrosis. Leveraging advanced PEGylation technology to optimize drug delivery and therapeutic efficacy, Prolong Pharmaceuticals' lead candidate, PP-007 (Sanguinate), is engineered to enhance oxygen delivery to hypoxic tissues. This commitment to cutting-edge biopharma solutions positions the company as a key player in revolutionizing treatments for severe and life-threatening illnesses.
How much funding has Prolong Pharmaceuticals, LLC. raised?
Prolong Pharmaceuticals, LLC. has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Prolong Pharmaceuticals, LLC.
PPP
Public-Private Partnership
What's next for Prolong Pharmaceuticals, LLC.?
The recent major strategic investment provides Prolong Pharmaceuticals with substantial capital to advance its clinical pipeline and further develop its innovative PEGylation technology. As a clinical-stage entity, this financing is crucial for progressing its lead candidate, PP-007 (Sanguinate), through further trials and regulatory processes. The company's focus on high-impact therapeutic areas like CNS, Hematology, and Respiratory Disorders, coupled with its unique technological approach, suggests a trajectory aimed at significant market penetration and addressing severe health challenges. Future growth will likely involve continued research and development, strategic partnerships, and potentially further funding rounds to support commercialization efforts.
See full Prolong Pharmaceuticals, LLC. company page
